RecruitingPhase 2NCT05709314

A Study of AMDX-2011P in Participants With CAA

A Phase 2, Open-Label Study of AMDX-2011P as a Retinal Tracer in Participants With Cerebral Amyloid Angiopathy (CAA)

Sponsor

Amydis Inc.

Enrollment

25 participants

Start Date

Jul 9, 2024

Study Type

INTERVENTIONAL

Conditions

Cerebral Amyloid Angiopathy

Summary

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AMDX-2011P for people with cerebral amyloid angiopathy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.